Phase I study of OSI-906, dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in combination with erlotinib (E) in patients with advanced solid tumors. Conference Paper uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Identity
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Macaulay, VM
  • Middleton, MR
  • Eckhardt, SG
  • Juergens, Rosalyn
  • Stephens, AW
  • Poondru, S
  • McCarthy, SP
  • Gadgeel, SM

publication date

  • May 20, 2010